Cancer Biology Department was established in 1980 with primary research focus area on Cell Biology, Molecular Endocrinology and Biochemistry which has now metamorphosed into 5 state of the art research laboratories as under:

The Department is involved in translational cancer research in and caters advanced diagnostic services for cancer patients. The department offers MSc in Cancer Biology and PhD in Life Sciences in affiliation with Gujarat University and imparting quality education with active cancer research.
Microarray, Next Generation sequencing, ddPCR and BSL II Culture facility is established for the translational cancer research.

Immunohaematology Lab 

Facility available :
The lab is well equipped with advanced diagnostic instruments such 2 ULTRA and 3 Ventana Benchmark XT automated Immunostainers, and FACS Lyric flow cytometer.

Clinical Services :
The lab works in co-ordination with Onco-pathology department by performing immunohistochemistry with two ULTRA and three Ventana Benchmark XT automated Immunostainers and leukemia/lymphoma immunophenotyping with FACS FACS Lyric flow cytometer to aid histopathological diagnosis and haematological diagnosis, respectively.

Academic Activities :
The lab staff is involved in teaching of MSc Cancer Biology, and PhD students. The division enrols MSc dissertation students from other colleges, as well as MSc, MPharm, MDS and MD students as observers.

Research Activities :
The lab is involved in translational cancer research and seeks to accelerate the application of discoveries in the laboratory to clinical practice. It is based on identification of cellular and molecular changes that occur during pathogenesis of the cancer and during cancer progression which cause therapeutic resistance.
The main areas of research include translational cancer research and seeks to accelerate the application of discoveries in the laboratory to clinical practice. It is based on identification of cellular and molecular changes that occur during pathogenesis of the cancer and during cancer progression which cause therapeutic resistance. The current research focus on detection of Mismatch repair deficiency in endometrial and colon cancer by NGS and immunohistochemistry. Also a 19 gene panel by NGS would be evaluated in these patients to study the most specific mutations in endometrial patients that would help in their treatment planning and possibly design a protein panel based on it. Further, PD-L1 expression studied by immunohistochemistry for their prognostic and therapeutic significance in different malignancy including TNBC, Lung cancer and Oral cancer. ALK-1 mutation is being evaluated in Lung Cancer. In endocrine resistant breast cancer CDK4/6, Cyclin D, ERα, PIK3CA is being evaluated to help find an alternative treatment line in patients who are resistant to endocrine therapy. In addition, lab also evaluates minimal residual disease (MRD) detection by flow cytometry in Acute Leukemia.